Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.46 |
| ▸ | CTSD | P07339 | 4/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477363 | 0.97 | BACE1 (0.46) | BACE1CTSDNOD1FOLH1BACE2 | |
| SCHEMBL29376100 | 0.95 | BACE1 (0.48) | BACE1CTSDNOD1FOLH1BACE2 | |
| SCHEMBL29765278 | 0.94 | BACE1 (0.48) | BACE1CTSDNOD1FOLH1BACE2 | |
| SCHEMBL30768075 | 0.94 | BACE1 (0.48) | BACE1CTSDNOD1FOLH1BACE2 | |
| SCHEMBL31429591 | 0.90 | FOLH1 (0.48) | NOD1FOLH1DPP4DPP8DPP9 | |
| SCHEMBL29886748 | 0.89 | BACE1 (0.53) | BACE1CTSDBACE2 | |
| SCHEMBL38659209 | 0.88 | NMT2 (0.45) | BACE1CTSDFOLH1BACE2 | |
| SCHEMBL30767177 | 0.88 | NOD1 (0.49) | BACE1CTSDNOD1DPP4DPP8 | |
| SCHEMBL30767162 | 0.88 | NOD1 (0.49) | BACE1CTSDNOD1DPP4DPP8 | |
| SCHEMBL30193334 | 0.88 | FOLH1 (0.46) | NOD1FOLH1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540161-B2 | Linkers | BICYCLETX LIMITED (GB) | 2026-02-03 | — | — | US | disclosed |
| CN-116348476-A | Peptide-based linkers | 拜斯科技术开发有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4188938-A1 | PEPTIDE-BASED LINKERS | BicycleTX Limited (GB) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022029420-A1 | PEPTIDE-BASED LINKERS | BICYCLETX LIMITED (GB) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540161-B2 | Linkers | ADM2, CDA, DCTD | BACE1 1756/4885CTSD 2009/4885NOD1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.